Ono Pharmaceutical Co., Ltd. (TYO:4528)
Japan · Delayed Price · Currency is JPY 2,490.00
+20.00 (0.81%)
Sep 3, 2026, 3:30 PM JST
Ono Pharmaceutical Ratios and Metrics
Market cap in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 1,160,671 | 1,179,703 | 752,707 | 1,152,917 | 1,349,755 | 1,512,876 | |
Market Cap Growth | 45.08% | 56.73% | -34.71% | -14.58% | -10.78% | 4.88% |
Enterprise Value | 1,064,058 | 1,121,376 | 741,730 | 1,065,259 | 1,255,982 | 1,465,094 |
Last Close Price | 2470.00 | 2510.50 | 1540.73 | 2257.81 | 2467.14 | 2673.98 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 15.23 | 16.91 | 15.04 | 9.01 | 11.97 | 18.79 |
Forward PE | 16.48 | 17.31 | 11.12 | 10.24 | 10.81 | 13.49 |
PS Ratio | 2.30 | 2.29 | 1.55 | 2.29 | 3.02 | 4.19 |
PB Ratio | 1.33 | 1.38 | 0.96 | 1.44 | 1.81 | 2.29 |
P/TBV Ratio | 2.37 | 2.49 | 1.75 | 1.57 | 2.01 | 2.56 |
P/FCF Ratio | 9.02 | 9.02 | 9.77 | 10.81 | 8.75 | 26.86 |
P/OCF Ratio | 8.63 | 8.62 | 9.13 | 10.42 | 8.46 | 24.47 |
PEG Ratio | - | 37.20 | 1.26 | 1.30 | 1.39 | 0.81 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 2.11 | 2.17 | 1.52 | 2.12 | 2.81 | 4.05 |
EV/EBITDA Ratio | 7.69 | 8.33 | 8.36 | 5.97 | 7.50 | 11.40 |
EV/EBIT Ratio | 10.55 | 11.57 | 12.00 | 6.65 | 8.37 | 13.22 |
EV/FCF Ratio | 8.27 | 8.57 | 9.63 | 9.99 | 8.14 | 26.01 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.13 | 0.14 | 0.19 | 0.01 | 0.01 | 0.01 |
Debt / EBITDA Ratio | 0.85 | 0.90 | 1.65 | 0.05 | 0.05 | 0.07 |
Debt / FCF Ratio | 0.91 | 0.93 | 1.90 | 0.08 | 0.06 | 0.16 |
Net Debt / Equity Ratio | -0.12 | -0.14 | -0.08 | -0.20 | -0.12 | -0.09 |
Net Debt / EBITDA Ratio | -0.74 | -0.86 | -0.70 | -0.88 | -0.52 | -0.47 |
Net Debt / FCF Ratio | -0.80 | -0.89 | -0.81 | -1.47 | -0.56 | -1.07 |
Asset Turnover | 0.48 | 0.48 | 0.49 | 0.56 | 0.55 | 0.49 |
Inventory Turnover | 2.11 | 2.14 | 2.40 | 2.72 | 2.54 | 2.31 |
Quick Ratio | 2.64 | 2.34 | 2.32 | 2.92 | 1.71 | 2.56 |
Current Ratio | 3.28 | 2.86 | 3.07 | 3.99 | 2.81 | 4.27 |
Return on Equity (ROE) | 9.26% | 8.50% | 6.32% | 16.56% | 16.02% | 12.39% |
Return on Assets (ROA) | 5.98% | 5.58% | 3.91% | 11.16% | 11.57% | 9.32% |
Return on Invested Capital (ROIC) | 10.08% | 9.97% | 7.64% | 19.25% | 18.70% | 14.34% |
Return on Capital Employed (ROCE) | 10.60% | 10.30% | 6.70% | 19.80% | 19.80% | 16.50% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 6.57% | 5.91% | 6.65% | 11.10% | 8.35% | 5.32% |
FCF Yield | 11.09% | 11.09% | 10.23% | 9.25% | 11.43% | 3.72% |
Dividend Yield | 3.24% | 3.19% | 5.19% | 3.54% | 2.84% | 2.09% |
Payout Ratio | 49.32% | 53.80% | 74.96% | 29.05% | 26.38% | 34.36% |
Buyback Yield / Dilution | -0.02% | -0.04% | 2.14% | 1.70% | 1.65% | 0.54% |
Total Shareholder Return | 3.25% | 3.14% | 7.33% | 5.24% | 4.48% | 2.63% |